StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for HURA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $2.51 | $2.46 | -1.99% | 1.0M |
| 05-20 | $2.44 | $2.39 | -2.05% | 0.6M |
| 05-21 | $2.35 | $2.34 | -0.43% | 0.4M |
| 05-22 | $2.33 | $2.50 | +7.30% | 0.6M |
| 05-26 | $2.50 | $2.45 | -2.00% | 0.5M |
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | Not available | $-30.05M | Not available | Not available |
Net Income | $-7.54M | $-30.05M | $-23.29M | $-9.52M |
EPS (Diluted) | $-0.13 | $-0.63 | $-0.50 | $-0.36 |
Total Assets | $29.70M | $27.35M | $25.70M | $34.62M |
Total Liabilities | $6.51M | $6.42M | $8.92M | $15.17M |
Cash & Equivalents | $6.30M | $3.62M | $2.70M | $8.51M |
Free Cash Flow OCF − CapEx | $-4.46M | $-27.71M | $-22.12M | $-11.03M |
Shares Outstanding | 63.58M | 59.34M | 51.25M | 49.91M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.